Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $755.66 million. The enterprise value is $814.25 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 265.15 million shares outstanding. The number of shares has increased by 16.95% in one year.
| Current Share Class | 265.15M |
| Shares Outstanding | 265.15M |
| Shares Change (YoY) | +16.95% |
| Shares Change (QoQ) | +12.21% |
| Owned by Insiders (%) | 2.02% |
| Owned by Institutions (%) | 42.98% |
| Float | 259.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.36 |
| Forward PS | 3.03 |
| PB Ratio | 26.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.00 |
| EV / EBITDA | 34.87 |
| EV / EBIT | 203.61 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 6.70.
| Current Ratio | 1.98 |
| Quick Ratio | 1.77 |
| Debt / Equity | 6.70 |
| Debt / EBITDA | 6.91 |
| Debt / FCF | n/a |
| Interest Coverage | 0.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 0.88% |
| Return on Invested Capital (ROIC) | 1.69% |
| Return on Capital Employed (ROCE) | 1.76% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | -$201,569 |
| Employee Count | 181 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.68 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +115.91% in the last 52 weeks. The beta is 0.68, so AKBA's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | +115.91% |
| 50-Day Moving Average | 3.08 |
| 200-Day Moving Average | 2.69 |
| Relative Strength Index (RSI) | 46.98 |
| Average Volume (20 Days) | 3,002,339 |
Short Selling Information
The latest short interest is 27.36 million, so 10.32% of the outstanding shares have been sold short.
| Short Interest | 27.36M |
| Short Previous Month | 27.09M |
| Short % of Shares Out | 10.32% |
| Short % of Float | 10.53% |
| Short Ratio (days to cover) | 7.09 |
Income Statement
In the last 12 months, AKBA had revenue of $203.73 million and -$36.48 million in losses. Loss per share was -$0.16.
| Revenue | 203.73M |
| Gross Profit | 169.55M |
| Operating Income | 4.00M |
| Pretax Income | -36.48M |
| Net Income | -36.48M |
| EBITDA | 23.35M |
| EBIT | 4.00M |
| Loss Per Share | -$0.16 |
Full Income StatementBalance Sheet
The company has $137.31 million in cash and $195.90 million in debt, giving a net cash position of -$58.59 million or -$0.22 per share.
| Cash & Cash Equivalents | 137.31M |
| Total Debt | 195.90M |
| Net Cash | -58.59M |
| Net Cash Per Share | -$0.22 |
| Equity (Book Value) | 29.22M |
| Book Value Per Share | 0.11 |
| Working Capital | 115.94M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.40 million and capital expenditures -$148,000, giving a free cash flow of -$2.55 million.
| Operating Cash Flow | -2.40M |
| Capital Expenditures | -148,000 |
| Free Cash Flow | -2.55M |
| FCF Per Share | -$0.01 |
Full Cash Flow StatementMargins
Gross margin is 83.22%, with operating and profit margins of 1.96% and -17.91%.
| Gross Margin | 83.22% |
| Operating Margin | 1.96% |
| Pretax Margin | -17.91% |
| Profit Margin | -17.91% |
| EBITDA Margin | 11.46% |
| EBIT Margin | 1.96% |
| FCF Margin | n/a |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.95% |
| Shareholder Yield | -16.95% |
| Earnings Yield | -4.83% |
| FCF Yield | -0.34% |
Analyst Forecast
The average price target for AKBA is $6.90, which is 142.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.90 |
| Price Target Difference | 142.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 25.49% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -4.88 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.88 |
| Piotroski F-Score | 4 |
